Site Loader

It is not long since the treatment options for metastatic prostate cancer have been introduced to mankind. In such revolutionary period many non-hormonal and hormonal agents like Enzalutamide have been incorporated as a vital treatment option for prostate cancer and it can be said that with the use of Enzalutamide the overall patient survival rate went up than other therapeutic agents. Being a non-steroidal 2nd generation anti-androgen it was approved for treating the metastatic CRPC, even if it was used in post-docetaxel and chemotherapy-naïve setting. In this study the pharmacological characteristics of enzalutamide, the efficacy studies which made it possible to approve this anti-androgen as well as its place in the consecutive treatment and management of metastatic prostate cancer is discussed here.

Post Author: admin


I'm Irma!

Would you like to get a custom essay? How about receiving a customized one?

Check it out